Endocrine Society Concerned Over Scaling Back ACA Contraception Coverage

The Endocrine Society expressed concerns Friday with the presidential administration’s new rules that would scale back the Affordable Care Act’s contraception coverage mandate.

The Society called for future health reform efforts to include continued access to no-cost hormonal contraception in a position statement issued last month.

The rules, which took effect Friday, allow companies to stop covering contraceptive services for their workers if they have religious or moral objections. The move will reduce some women’s ability to access birth control at no cost.

No-cost hormonal contraceptive services allow a woman to effectively plan if and when she becomes pregnant. This has a positive impact on families’ socioeconomic status and health. The resulting reduction in unplanned pregnancies also has a positive impact on healthcare costs.

Hormonal contraception’s health benefits extend beyond family planning. Endocrinologists frequently prescribe hormonal contraception to treat a variety of conditions, such as polycystic ovary syndrome (PCOS). Many birth control pill users use this contraceptive method to treat excessive menstrual bleeding, menstrual pain and acne. Hormonal contraception also can reduce a woman’s risk of developing ovarian and endometrial cancer.

By allowing employers to revert to pre-ACA cost-sharing requirements, the rules will increase the number of women who are unable to afford contraception.

You may also like

  • Destination Albuquerque: Previewing the 1st International Conference on Steroid Hormones and Receptors

    Building on a legacy that has lasted for a quarter of a century and now sponsored by the Endocrine Society, the 1st International Conference on Steroid Hormones and Receptors will be held next month at University of New Mexico Comprehensive Cancer Center in Albuquerque. Endocrine News talks to conference chairs Eric R. Prossnitz, PhD, and…

  • Meet New Endocrine Society President, John Newell-Price, MD, PhD

    The Endocrine Society is pleased to welcome its president for 2024 – 2025, John Newell-Price, MD, PhD, FRCP, who took office during ENDO 2024 in Boston. Newell-Price is Professor of Endocrinology at the University of Sheffield, United Kingdom. He is also head of the Endocrinology Service at Sheffield Teaching Hospitals NHS Foundation Trust and of…

Find more in